Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
27.09. | Vicebio raises $100m for vaccines and other bio financings | ||
26.09. | Mirai Bio launches with plan to help genetic med developers | ||
26.09. | AZ gets sought-after lung cancer approval for Tagrisso | ||
26.09. | Second Niemann-Pick approval brings more hope to patients | ||
26.09. | Obesity drug developer BioAge raises $198m in IPO | ||
26.09. | Pfizer pulls sickle cell med Oxbryta off market after deaths | ||
26.09. | MSD hits a hurdle with its LAG-3 programme | ||
25.09. | Aurion launches eye disease cell therapy in its first market | ||
25.09. | Novo Nordisk CEO reticent on lowering semaglutide prices | ||
25.09. | Surfing on new Duchenne data, Wave charges $175m offering | ||
25.09. | Lilly gets second approval, in Japan, for Alzheimer's drug | ||
25.09. | AI firm Generate signs $1bn discovery deal with Novartis | ||
24.09. | MHRA's AI as medical device pilot opens for applicants | ||
24.09. | Astellas claims EU okay for first claudin 18.2 cancer drug | ||
24.09. | UCB, Biogen lupus drug scores in phase 3 trial | ||
24.09. | Roche launches 'revolutionary' pathogen detection tech | ||
24.09. | Ipsen crosses EU finish line with Alagille syndrome drug | ||
23.09. | FDA clears RHYTHM AI's new algorithm for atrial fibrillation | ||
23.09. | Sanofi's Sarclisa gets one up on rival Darzalex in myeloma | ||
23.09. | FDA clears first drug for Niemann-Pick disease | ||
23.09. | J&J tries to push talc bankruptcy over the line once again | ||
23.09. | FTC sues PBMs over 'perverse' rebate system | ||
20.09. | Sanofi's tolebrutinib cuts MS progression by 31% in trial | ||
20.09. | J&J nets another key approval for blockbuster hope Rybrevant | ||
20.09. | Job losses loom at Achilles as TIL therapy platform is cut |